Clinical Trial Update: Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of HR20013 for injection in patients undergoing highly emetogenic chemotherapy to prevent nausea and vomiting has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prevention of Nausea and Vomiting Caused By Highly Emetogenic Chemotherapy

Drugs mentioned

• HR20013

Snippet

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Conditions: Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy | Phase 3 | Status: COMPLETED